Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody aims to calm ankylosing spondylitis

NCT ID NCT06250062

Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This phase 2 trial tests an experimental drug called JS005 in adults with active ankylosing spondylitis, a type of arthritis that mainly affects the spine. JS005 is a lab-made antibody that blocks IL-17A, a protein involved in inflammation. The study compares JS005 injections to a placebo to see if it reduces symptoms like back pain and stiffness over 16 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an experimental anti-IL-17A antibody called JS005
What this could lead to
If successful, JS005 could offer a new treatment option for people with active ankylosing spondylitis, reducing pain and stiffness.
What could go wrong
This is an early phase 2 trial, so results may not confirm effectiveness. Side effects from blocking IL-17A, such as infections, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

265 people

The number who actually took part.

Started

Jan 2024

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects voluntarily particpate in this clinical study and sign the informed consent form. 2. Male and female patients aged 18-75 years at the time of screening (both inclusive) 3. Meet the diagnosis of active Ankylosing Spondylitis(AS), have a record of radiological evidence consistent with the Modified New York Classification Criteria for ankylosing spondylitis as revised in 1984 4. Diagnosis of active AS (active AS is defined as: BASDAI \>= 4, total back pain score \>=4, and BASDAI second question spinal pain score \>=4) Exclusion Criteria: 1. Pregnant or lactating women. 2. Active diseases that may confound the evaluation of JS005: other autoimmune inflammatory diseases (including but not limited to systemic lupus erythematosus, rheumatoid arthritis, sarcoidosis, vasculitis, etc.) or chronic pain other than ankylosing spondylitis (including but not limited to fibromyalgia, osteoarthritis, etc.). 4\. Active inflammatory bowel disease within 6 months prior to randomization. 5. Recurrent anterior uveitis or acute anterior uveitis within the last 4 weeks prior to randomization. 6\. History or evidence of active or latent tuberculosis (TB), defined as a positive interferon gamma release assay (IGRA) or purified protein derivative (PPD) at the time of screening. 7. Positive hepatitis B virus test result 8. Prior exposure to JS005 or any other biologic that directly targets IL-17 or the IL-17 receptor. 9\. use of \>= 2 TNF-α inhibitors.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ankylosing spondylitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ankylosing spondylitis

Contacts and locations

Locations

  • Beijing Chao-yang Hospital,Capital Medical University

    Beijing, Beijing Municipality, 100020, China

  • Bethune First Hospital Of Jilin University

    Changchun, Jilin, 130021, China

  • Binzhou Medical University Hospital

    Binzhou, Shandong, 256603, China

  • Dongguan People's Hospital

    Dongguan, Guangdong, 523018, China

  • First Affiliated Hospital of Gannan Medical University

    Ganzhou, Jiangxi, 341000, China

  • Gansu Provincial Hospital

    Lanzhou, Gansu, 730000, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, 510180, China

  • Huizhou Central People's Hospital

    Huizhou, Guangdong, 516001, China

  • Jieyang People's Hospital

    Jieyang, Guangdong, 522000, China

  • Jilin Province People's Hospital

    Jilin City, Changchun, 130021, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, 210008, China

  • Nanyang Central Hospital

    Nanyang, Henan, 473003, China

  • Pingxiang People's Hospital

    Pingxiang, Jiangxi, 337055, China

  • Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, 030001, China

  • Shandong Provincial Hospital

    Jinan, Shandong, 250021, China

  • Shanghai Changzheng Hospital

    Shanghai, Shanghai Municipality, 200003, China

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, 518020, China

  • Shenzhen Second People's Hospital

    Shenzhen, Guangdong, 518035, China

  • Sun Yat-sen Memorial Hospital

    Guangzhou, Guangdong, 510120, China

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, 010030, China

  • The First Affiliated Hospital of Baotou Medical University

    Baotou, Inner Mongolia, 014010, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330006, China

  • The First Affiliated Hospital of Shantou University Medical College

    Shantou, Guangdong, 515041, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325000, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, 110001, China

  • The First People's Hospital of Jiujiang City

    Jiujiang, Jiangxi, 332000, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330006, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510630, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, 610041, China

  • Xinjiang Uygur Autonomous Region People's Hospital

    Ürümqi, Xinjiang, 830001, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, 221006, China

  • Zaozhuang Municipal Hospital

    Zaozhuang, Shandong, 277100, China

  • Zhengzhou Central Hospital

    Zhengzhou, Henan, 450001, China

  • Zhongshan Hospital Xiamen University

    Xiamen, Fujian, 361004, China

  • Zhujiang Hospital of Southren Medical University

    Guangzhou, Guangdong, 510280, China

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, 412007, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.